Coronavirus disease (COVID-19) chilblains is a well-reported cutaneous pattern of severe acute respiratory syndrome coronavirus (SARS-CoV-2). Through this narrative review, we provide an evidence-based overview of idiopathic and secondary chilblains, distinguishing features of COVID-19 chilblains, and a systematic clinical approach to history, examination, investigations, and treatment. In the absence of cold or damp exposure, COVID-19 should be considered as a cause of acute chilblains. The timing of onset of COVID-19 chilblains relative to active SARS-CoV-2 viremia remains unclear. Patients with suspected COVID-19 chilblains should thus follow public health guidelines for COVID-19 testing and self-isolation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1203475420937978 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of skin manifestations in patients with COVID-19: a systematic review and meta-analysis.
Front Med (Lausanne)
August 2024
Health Science Graduate Program, School of Health Sciences, University of Brasilia, Brasília, Brazil.
Article Synopsis
- This systematic review aimed to analyze the prevalence and characteristics of skin manifestations associated with COVID-19, as these can assist in diagnosis, especially since the details were unclear.
- The review included 31 studies with over 10,000 patients and found that the overall prevalence of skin manifestations was about 29%, predominantly observed in Africa, with hands, feet, and trunk being most affected.
- Patients with milder COVID-19 symptoms showed more specific skin conditions compared to those with severe cases, indicating that skin assessments should be a key part of evaluating and diagnosing COVID-19, particularly in adults and the elderly.
Background incidence rates of health outcomes of interest for COVID-19 vaccine safety monitoring in a US population: a claims database analysis.
BMJ Open
July 2024
Aetion Inc, New York, New York, USA.
Objective: To evaluate background incidence rates of 59 health outcomes of interest (HOI) in a diverse population, including important subpopulations, during the pre-COVID-19 era (1 January 2017-31 December 2019) and the COVID-19 era (1 March 2020-31 December 2020), before the introduction of COVID-19 vaccines.
Design: Observational retrospective cohort study. Annual incidence rates and 95% confidence intervals (CIs) of HOIs were estimated for each population of interest, stratified by: age, sex, age and sex and seasonality.
Diagnosis and management of COVID toes in outpatients: a case report.
J Med Case Rep
June 2024
University Center for Primary Care and Public Health, Unisanté, Lausanne, Switzerland.
Article Synopsis
- The most common skin condition linked to COVID-19 is pseudochilblains, commonly referred to as "COVID toes," which are hard to diagnose without a specific test.
- Two women, aged 30 and 22, were treated for these lesions during the pandemic; neither showed respiratory symptoms, but one had positive serology and both had distinct clinical difficulties post-cold exposure.
- Their cases highlight the variability of COVID-19 symptoms, suggesting that skin lesions may indicate an interferon response and should be considered in diagnoses during primary care visits.
Reconstructive Limb Salvage After COVID-19-Induced Gangrene and Amputation.
Cureus
May 2024
Vascular Surgery, Keck School of Medicine of USC (University of Southern California), Los Angeles, USA.
This case series describes the clinical course and reconstructive methods utilized for patients with diabetes and significant gangrene and necrosis following coronavirus disease 2019 (COVID-19) infection. COVID-19 produces mainly respiratory symptoms but has a variety of atypical presentations and sequelae. Serious complications are increased in patients with underlying medical conditions such as diabetes mellitus.
View Article and Find Full Text PDFAn Unusual Presentation of Erythema Multiforme Following the Administration of Pfizer-BioNTech COVID-19 mRNA Vaccine in a Pediatric Patient.
Cureus
April 2024
College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Coronavirus disease 2019 (COVID-19) caused a global calamity that forced emergency use authorization to Pfizer-BioNTech COVID-19 (BNT162b2) vaccine. It is efficacious in preventing symptomatic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in seronegative recipients. The safety profile is still unclear; however, commonly reported symptoms post-vaccination are fatigue, headache, muscle pain, chills, and injection-site pain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!